In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Beta Bionics Inc (NASDAQ: BBNX) closed at $31.09 in the last session, down -0.83% from day before closing price of $31.35. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 0.64 million shares were traded. BBNX stock price reached its highest trading level at $31.78 during the session, while it also had its lowest trading level at $30.81.
Ratios:
We take a closer look at BBNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 10.64. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 01, 2025, Goldman Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $26.
On June 16, 2025, Truist started tracking the stock assigning a Buy rating and target price of $26.Truist initiated its Buy rating on June 16, 2025, with a $26 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Mark Hopman bought 2,061 shares for $30.66 per share.
Mensinger Mike sold 1,063 shares of BBNX for $31,184 on Dec 02 ’25. The Chief Product Officer now owns 90,752 shares after completing the transaction at $29.34 per share. On Dec 02 ’25, another insider, Feider Stephen, who serves as the Chief Financial Officer of the company, sold 1,427 shares for $29.34 each. As a result, the insider received 41,862 and left with 42,614 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 1368725760 and an Enterprise Value of 1147725824. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.45 while its Price-to-Book (P/B) ratio in mrq is 4.64. Its current Enterprise Value per Revenue stands at 12.958 whereas that against EBITDA is -17.047.
Stock Price History:
Over the past 52 weeks, BBNX has reached a high of $32.71, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is 13.76%, while the 200-Day Moving Average is calculated to be 64.16%.
Shares Statistics:
According to the various share statistics, BBNX traded on average about 769.69K shares per day over the past 3-months and 1212690 shares per day over the past 10 days. A total of 43.99M shares are outstanding, with a floating share count of 33.42M. Insiders hold about 24.09% of the company’s shares, while institutions hold 94.94% stake in the company. Shares short for BBNX as of 1765756800 were 4020336 with a Short Ratio of 5.22, compared to 1763078400 on 3572312. Therefore, it implies a Short% of Shares Outstanding of 4020336 and a Short% of Float of 10.290000000000001.
Earnings Estimates
The stock of Beta Bionics Inc (BBNX) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.34 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.64 and -$2.06 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.66, with 6.0 analysts recommending between -$1.27 and -$2.0.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $28.91M. It ranges from a high estimate of $29.8M to a low estimate of $28M. As of. The current estimate, Beta Bionics Inc’s year-ago sales were $20.44MFor the next quarter, 10 analysts are estimating revenue of $27.51M. There is a high estimate of $30.67M for the next quarter, whereas the lowest estimate is $24.2M.
A total of 10 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $97.9M, while the lowest revenue estimate was $96.5M, resulting in an average revenue estimate of $97.13M. In the same quarter a year ago, actual revenue was $65.12MBased on 10 analysts’ estimates, the company’s revenue will be $132.25M in the next fiscal year. The high estimate is $143.98M and the low estimate is $121M.
